Going beyond standard PGT-A. We analyze the entire embryo genome and report only clinically relevant, high-confidence findings.
Primarily assesses chromosome count. Detects aneuploidy, but may miss smaller genetic alterations.
Analyzes the genetic code itself. Can additionally detect disease-relevant variants when medically interpretable.
Standard PGT-A looks at chromosome number. Amidala looks at genetic content – within clearly defined medical boundaries.
Transfer recommended or not recommended – with medical rationale.
Findings are clinically interpreted and validated.
Unclear findings are flagged, not used for decision-making.
Designed for use via IVF clinics and medical counseling.
Results serve as physician decision support.
PGT-A primarily evaluates chromosome count. Amidala uses whole-genome analysis and can identify additional genetic risks when medically appropriate. Application is always mediated by clinical counseling.
We focus on high-confidence, clinically relevant findings – primarily well-characterized monogenic conditions with clear pathogenic variants.
Results are delivered as a detailed clinician report alongside a parent-friendly summary document.
Uncertain findings are labeled explicitly. We do not overinterpret – ambiguity is communicated, not glossed over.
Amidala is available through partner IVF clinics. We can help connect you with a suitable clinic or provide information for your medical team.
We connect you with a suitable partner clinic or provide information for medical counseling.